ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in High-Risk FL Regardless of POD24 Status"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in High-Risk FL Regardless of POD24 Status"

By Insights from 2023 ASCO® Annual Meeting FEATURING Reid Merryman

0 views

June 27, 2023

Comments 0

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson